Skip to main content
Top
Published in: Sports Medicine 11/2014

01-11-2014 | Review Article

The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations

Authors: Zsolt Murlasits, Zsolt Radák

Published in: Sports Medicine | Issue 11/2014

Login to get access

Abstract

The incidence of myopathy increases dramatically in statin users who also exercise, likely limiting the positive impact of this lifesaving medication. New evidence also indicates that statin use can directly compromise aerobic exercise capacity; however, we are just beginning to understand the interactions of statins with exercise training and adaptations. This review focuses on the interactions of statins with aerobic exercise capacity and training adaptations to summarize the available information and draw attention to the gaps in our current knowledge in this area. PubMed, Web of knowledge, and Google scholar databases were searched between January 2000 and December 2013 using the following terms and their combinations: statins, exercise, aerobic capacity, endurance training, adaptations. The reference lists of the relevant articles were also scanned for additional information. Considering the widespread use of statins and the need for exercise for cardiovascular health, a better understanding of the interactions of these interventions as well as practical solutions are needed to reduce statin adverse effects associated with exercise.
Literature
1.
go back to reference Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.PubMedPubMedCentral Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.PubMedPubMedCentral
3.
go back to reference Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013.
4.
go back to reference Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24(5):258–72.PubMed Baker SK, Tarnopolsky MA. Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med. 2001;24(5):258–72.PubMed
5.
go back to reference Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.PubMedCrossRef Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.PubMedCrossRef
6.
go back to reference Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9(8):1133–42.PubMedCrossRef Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9(8):1133–42.PubMedCrossRef
7.
go back to reference Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther. 2010;90(10):1530–42.PubMedPubMedCentralCrossRef Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther. 2010;90(10):1530–42.PubMedPubMedCentralCrossRef
8.
go back to reference Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208–12.PubMedCrossRef Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006;291(6):C1208–12.PubMedCrossRef
9.
go back to reference El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44(6):877–81.PubMedCrossRef El-Salem K, Ababneh B, Rudnicki S, Malkawi A, Alrefai A, Khader Y, et al. Prevalence and risk factors of muscle complications secondary to statins. Muscle Nerve. 2011;44(6):877–81.PubMedCrossRef
10.
go back to reference Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–65.PubMedCrossRef Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–65.PubMedCrossRef
11.
go back to reference Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O’Fallon KS, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008;200(1):121–5.PubMedCrossRef Kearns AK, Bilbie CL, Clarkson PM, White CM, Sewright KA, O’Fallon KS, et al. The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg. Atherosclerosis. 2008;200(1):121–5.PubMedCrossRef
12.
go back to reference Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol. 2009;587(Pt 1):219–30.PubMedPubMedCentralCrossRef Mallinson JE, Constantin-Teodosiu D, Sidaway J, Westwood FR, Greenhaff PL. Blunted akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. J Physiol. 2009;587(Pt 1):219–30.PubMedPubMedCentralCrossRef
13.
go back to reference Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181(1–2):E11–8.PubMedPubMedCentralCrossRef Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181(1–2):E11–8.PubMedPubMedCentralCrossRef
14.
go back to reference Reust CS, Curry SC, Guidry JR. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. West J Med. 1991;154(2):198–200.PubMedPubMedCentral Reust CS, Curry SC, Guidry JR. Lovastatin use and muscle damage in healthy volunteers undergoing eccentric muscle exercise. West J Med. 1991;154(2):198–200.PubMedPubMedCentral
15.
go back to reference Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 2005;314(3):1032–41.PubMedCrossRef Sacher J, Weigl L, Werner M, Szegedi C, Hohenegger M. Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells. J Pharmacol Exp Ther. 2005;314(3):1032–41.PubMedCrossRef
16.
go back to reference Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40(2):163–71.PubMedCrossRef Sinzinger H, Wolfram R, Peskar BA. Muscular side effects of statins. J Cardiovasc Pharmacol. 2002;40(2):163–71.PubMedCrossRef
17.
go back to reference Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8(3):333–8.PubMedCrossRef Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008;8(3):333–8.PubMedCrossRef
18.
go back to reference Tanaka S, Sakamoto K, Yamamoto M, Mizuno A, Ono T, Waguri S, et al. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J Pharmacol Sci. 2010;114(4):454–63.PubMedCrossRef Tanaka S, Sakamoto K, Yamamoto M, Mizuno A, Ono T, Waguri S, et al. Mechanism of statin-induced contractile dysfunction in rat cultured skeletal myofibers. J Pharmacol Sci. 2010;114(4):454–63.PubMedCrossRef
19.
20.
go back to reference Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85(5):459–65.PubMed Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther. 2005;85(5):459–65.PubMed
21.
go back to reference Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27–42.PubMedCrossRef Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol. 2008;93(1):27–42.PubMedCrossRef
22.
go back to reference Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 2008;82(17–18):969–75.PubMedCrossRef Kobayashi M, Chisaki I, Narumi K, Hidaka K, Kagawa T, Itagaki S, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sci. 2008;82(17–18):969–75.PubMedCrossRef
23.
go back to reference Mascitelli L, Pezzetta F. Physical activity in statin-treated patients. Int J Cardiol. 2009;134(1):136–7.PubMedCrossRef Mascitelli L, Pezzetta F. Physical activity in statin-treated patients. Int J Cardiol. 2009;134(1):136–7.PubMedCrossRef
24.
go back to reference Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–94.PubMedPubMedCentral Parker BA, Thompson PD. Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes. Exerc Sport Sci Rev. 2012;40(4):188–94.PubMedPubMedCentral
25.
go back to reference Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 2011;111(5):1477–83.PubMedCrossRef Bouitbir J, Charles AL, Rasseneur L, Dufour S, Piquard F, Geny B, et al. Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress. J Appl Physiol. 2011;111(5):1477–83.PubMedCrossRef
26.
go back to reference Opie LH. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther. 2013;27(6):569–72.PubMedCrossRef Opie LH. Exercise-induced myalgia may limit the cardiovascular benefits of statins. Cardiovasc Drugs Ther. 2013;27(6):569–72.PubMedCrossRef
27.
go back to reference Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469–79.PubMedCrossRef Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve. 2010;42(4):469–79.PubMedCrossRef
28.
go back to reference Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011;44(6):882–9.PubMedCrossRef Meador BM, Huey KA. Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise. Muscle Nerve. 2011;44(6):882–9.PubMedCrossRef
29.
go back to reference Semple SJ. Statin therapy, myopathy and exercise: a case report. Lipids Health Dis. 2012;16(11):40.CrossRef Semple SJ. Statin therapy, myopathy and exercise: a case report. Lipids Health Dis. 2012;16(11):40.CrossRef
30.
go back to reference Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4):525–8.PubMedPubMedCentralCrossRef Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol. 2004;57(4):525–8.PubMedPubMedCentralCrossRef
31.
go back to reference Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206–10.PubMedCrossRef Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism. 1997;46(10):1206–10.PubMedCrossRef
32.
go back to reference Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol. 2013;62(8):715–6.PubMedCrossRef Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol. 2013;62(8):715–6.PubMedCrossRef
33.
go back to reference Lim S, Despres JP, Koh KK. Prevention of atherosclerosis in overweight/obese patients: in need of novel multi-targeted approaches. Circ J. 2011;75(5):1019–27.PubMedCrossRef Lim S, Despres JP, Koh KK. Prevention of atherosclerosis in overweight/obese patients: in need of novel multi-targeted approaches. Circ J. 2011;75(5):1019–27.PubMedCrossRef
34.
go back to reference Monda KL, Ballantyne CM, North KE. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the atherosclerosis risk in communities study. J Lipid Res. 2009;50(8):1685–91.PubMedPubMedCentralCrossRef Monda KL, Ballantyne CM, North KE. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the atherosclerosis risk in communities study. J Lipid Res. 2009;50(8):1685–91.PubMedPubMedCentralCrossRef
35.
go back to reference Chomistek AK, Chiuve SE, Jensen MK, Cook NR, Rimm EB. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc. 2011;43(10):1884–90.PubMedPubMedCentralCrossRef Chomistek AK, Chiuve SE, Jensen MK, Cook NR, Rimm EB. Vigorous physical activity, mediating biomarkers, and risk of myocardial infarction. Med Sci Sports Exerc. 2011;43(10):1884–90.PubMedPubMedCentralCrossRef
36.
go back to reference Veiga OL, Gomez-Martinez S, Martinez-Gomez D, Villagra A, Calle ME, Marcos A, et al. Physical activity as a preventive measure against overweight, obesity, infections, allergies and cardiovascular disease risk factors in adolescents: AFINOS study protocol. BMC Public Health. 2009;9:475 2458-9-475.PubMedPubMedCentralCrossRef Veiga OL, Gomez-Martinez S, Martinez-Gomez D, Villagra A, Calle ME, Marcos A, et al. Physical activity as a preventive measure against overweight, obesity, infections, allergies and cardiovascular disease risk factors in adolescents: AFINOS study protocol. BMC Public Health. 2009;9:475 2458-9-475.PubMedPubMedCentralCrossRef
37.
go back to reference Cotter KA, Lachman ME. No strain, no gain: psychosocial predictors of physical activity across the adult lifespan. J Phys Act Health. 2010;7(5):584–94.PubMedPubMedCentral Cotter KA, Lachman ME. No strain, no gain: psychosocial predictors of physical activity across the adult lifespan. J Phys Act Health. 2010;7(5):584–94.PubMedPubMedCentral
38.
go back to reference Stamatakis E, Hamer M, Primatesta P. Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up. Heart. 2009;95(6):448–53.PubMedCrossRef Stamatakis E, Hamer M, Primatesta P. Cardiovascular medication, physical activity and mortality: cross-sectional population study with ongoing mortality follow-up. Heart. 2009;95(6):448–53.PubMedCrossRef
39.
go back to reference Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. Circulation. 2010;122(16):1637–48.PubMedCrossRef Kokkinos P, Myers J. Exercise and physical activity: clinical outcomes and applications. Circulation. 2010;122(16):1637–48.PubMedCrossRef
40.
go back to reference Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–53.PubMedPubMedCentralCrossRef Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER database. J Lipid Res. 2010;51(6):1546–53.PubMedPubMedCentralCrossRef
41.
go back to reference Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381(9864):394–9.PubMedCrossRef Kokkinos PF, Faselis C, Myers J, Panagiotakos D, Doumas M. Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet. 2013;381(9864):394–9.PubMedCrossRef
42.
go back to reference Kokkinos P, Faselis C, Myers J, Kokkinos JP, Doumas M, Pittaras A, et al. Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. Am J Hypertens. 2014;27(3):422–30.PubMedCrossRef Kokkinos P, Faselis C, Myers J, Kokkinos JP, Doumas M, Pittaras A, et al. Statin therapy, fitness, and mortality risk in middle-aged hypertensive male veterans. Am J Hypertens. 2014;27(3):422–30.PubMedCrossRef
43.
go back to reference Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709–14.PubMedPubMedCentralCrossRef Mikus CR, Boyle LJ, Borengasser SJ, Oberlin DJ, Naples SP, Fletcher J, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709–14.PubMedPubMedCentralCrossRef
44.
go back to reference Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 2012;113(3):479–86.PubMedCrossRef Muraki A, Miyashita K, Mitsuishi M, Tamaki M, Tanaka K, Itoh H. Coenzyme Q10 reverses mitochondrial dysfunction in atorvastatin-treated mice and increases exercise endurance. J Appl Physiol. 2012;113(3):479–86.PubMedCrossRef
45.
go back to reference Panayiotou G, Paschalis V, Nikolaidis MG, Theodorou AA, Deli CK, Fotopoulou N, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports. 2013;23(5):556–67.PubMed Panayiotou G, Paschalis V, Nikolaidis MG, Theodorou AA, Deli CK, Fotopoulou N, et al. No adverse effects of statins on muscle function and health-related parameters in the elderly: an exercise study. Scand J Med Sci Sports. 2013;23(5):556–67.PubMed
46.
go back to reference Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr). 2008;30(4):283–91.CrossRef Traustadottir T, Stock AA, Harman SM. High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults. Age (Dordr). 2008;30(4):283–91.CrossRef
47.
go back to reference Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21(4):324–8.PubMedCrossRef Krishnan GM, Thompson PD. The effects of statins on skeletal muscle strength and exercise performance. Curr Opin Lipidol. 2010;21(4):324–8.PubMedCrossRef
48.
go back to reference Thompson PD, Parker BA, Clarkson PM, Pescatello LS, White CM, Grimaldi AS, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol. 2010;13(3):104–11.PubMedPubMedCentral Thompson PD, Parker BA, Clarkson PM, Pescatello LS, White CM, Grimaldi AS, et al. A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design. Prev Cardiol. 2010;13(3):104–11.PubMedPubMedCentral
49.
go back to reference Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. The effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. The effect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103.
50.
go back to reference Fuzi M, Palicz Z, Vincze J, Cseri J, Szombathy Z, Kovacs I, et al. Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats. J Muscle Res Cell Motil. 2012;32(6):391–401.PubMedCrossRef Fuzi M, Palicz Z, Vincze J, Cseri J, Szombathy Z, Kovacs I, et al. Fluvastatin-induced alterations of skeletal muscle function in hypercholesterolaemic rats. J Muscle Res Cell Motil. 2012;32(6):391–401.PubMedCrossRef
51.
go back to reference Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282–7.PubMedCrossRef Parker BA, Augeri AL, Capizzi JA, Ballard KD, Troyanos C, Baggish AL, et al. Effect of statins on creatine kinase levels before and after a marathon run. Am J Cardiol. 2012;109(2):282–7.PubMedCrossRef
52.
go back to reference Thompson PD, Clarkson PM, Rosenson RS. National lipid association statin safety task force muscle safety expert panel: an assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C–76C.PubMedCrossRef Thompson PD, Clarkson PM, Rosenson RS. National lipid association statin safety task force muscle safety expert panel: an assessment of statin safety by muscle experts. Am J Cardiol. 2006;97(8A):69C–76C.PubMedCrossRef
53.
go back to reference Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.PubMedCrossRef Scott D, Blizzard L, Fell J, Jones G. Statin therapy, muscle function and falls risk in community-dwelling older adults. QJM. 2009;102(9):625–33.PubMedCrossRef
54.
go back to reference Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism. 2009;58(7):1030–8.PubMedCrossRef Coen PM, Flynn MG, Markofski MM, Pence BD, Hannemann RE. Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage. Metabolism. 2009;58(7):1030–8.PubMedCrossRef
55.
go back to reference Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.PubMedCrossRef Draeger A, Monastyrskaya K, Mohaupt M, Hoppeler H, Savolainen H, Allemann C, et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol. 2006;210(1):94–102.PubMedCrossRef
56.
go back to reference Ballard KD, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230(1):121–4.PubMedPubMedCentralCrossRef Ballard KD, Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230(1):121–4.PubMedPubMedCentralCrossRef
57.
go back to reference Chung J, Brass EP, Ulrich RG, Hiatt WR. Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise. Clin Pharmacol Ther. 2008;83(2):243–50.PubMedCrossRef Chung J, Brass EP, Ulrich RG, Hiatt WR. Effect of atorvastatin on energy expenditure and skeletal muscle oxidative metabolism at rest and during exercise. Clin Pharmacol Ther. 2008;83(2):243–50.PubMedCrossRef
58.
go back to reference Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol. 2009;107(1):8–16.PubMedCrossRef Robinson MM, Hamilton KL, Miller BF. The interactions of some commonly consumed drugs with mitochondrial adaptations to exercise. J Appl Physiol. 2009;107(1):8–16.PubMedCrossRef
59.
go back to reference SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359:789–99.PubMedCrossRef SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S. SLCO1B1 variants and statin-induced myopathy: a genomewide study. N Engl J Med. 2008;359:789–99.PubMedCrossRef
60.
go back to reference Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210(2):337–43.PubMedCrossRef Ghatak A, Faheem O, Thompson PD. The genetics of statin-induced myopathy. Atherosclerosis. 2010;210(2):337–43.PubMedCrossRef
61.
go back to reference Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502(7471):377–80.PubMedPubMedCentralCrossRef Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, Chasman DI, et al. A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature. 2013;502(7471):377–80.PubMedPubMedCentralCrossRef
62.
go back to reference Yan Z, Okutsu M, Akhtar YN, Lira VA. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. J Appl Physiol. 2011;110(1):264–74.PubMedPubMedCentralCrossRef Yan Z, Okutsu M, Akhtar YN, Lira VA. Regulation of exercise-induced fiber type transformation, mitochondrial biogenesis, and angiogenesis in skeletal muscle. J Appl Physiol. 2011;110(1):264–74.PubMedPubMedCentralCrossRef
63.
go back to reference Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001;51(2):283–93.PubMedCrossRef Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res. 2001;51(2):283–93.PubMedCrossRef
64.
go back to reference Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003;93(8):697–9.PubMedCrossRef Jones SP, Teshima Y, Akao M, Marban E. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res. 2003;93(8):697–9.PubMedCrossRef
65.
go back to reference Wright DG, Lefer DJ. Statin mediated protection of the ischemic myocardium. Vascul Pharmacol. 2005;42(5–6):265–70.PubMedCrossRef Wright DG, Lefer DJ. Statin mediated protection of the ischemic myocardium. Vascul Pharmacol. 2005;42(5–6):265–70.PubMedCrossRef
66.
go back to reference Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33(11):1397–407.PubMedPubMedCentralCrossRef Bouitbir J, Charles AL, Echaniz-Laguna A, Kindo M, Daussin F, Auwerx J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33(11):1397–407.PubMedPubMedCentralCrossRef
67.
go back to reference Keller-Pinter A, Murlasits Z, Szucs G, Menesi D, Puskas L, Ferdinandy P, et al. Upregulation of squalene synthase in type IIB fibers is an early response for statin treatment. Neuromusc Disord. 2011;21(9–10):744–5.CrossRef Keller-Pinter A, Murlasits Z, Szucs G, Menesi D, Puskas L, Ferdinandy P, et al. Upregulation of squalene synthase in type IIB fibers is an early response for statin treatment. Neuromusc Disord. 2011;21(9–10):744–5.CrossRef
68.
go back to reference Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.PubMedCrossRef Westwood FR, Bigley A, Randall K, Marsden AM, Scott RC. Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity. Toxicol Pathol. 2005;33(2):246–57.PubMedCrossRef
69.
go back to reference Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005;338(3):1426–34.PubMedCrossRef Sirvent P, Bordenave S, Vermaelen M, Roels B, Vassort G, Mercier J, et al. Simvastatin induces impairment in skeletal muscle while heart is protected. Biochem Biophys Res Commun. 2005;338(3):1426–34.PubMedCrossRef
70.
go back to reference Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31(5):572–80.PubMedCrossRef Baker SK. Molecular clues into the pathogenesis of statin-mediated muscle toxicity. Muscle Nerve. 2005;31(5):572–80.PubMedCrossRef
71.
go back to reference Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145(1):91–8.PubMedCrossRef Flint OP, Masters BA, Gregg RE, Durham SK. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol. 1997;145(1):91–8.PubMedCrossRef
72.
go back to reference Casey PJ. Biochemistry of protein prenylation. J Lipid Res. 1992;33(12):1731–40.PubMed Casey PJ. Biochemistry of protein prenylation. J Lipid Res. 1992;33(12):1731–40.PubMed
76.
go back to reference McCarty MF. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses. 2001;56(1):12–6.PubMedCrossRef McCarty MF. Suppression of dolichol synthesis with isoprenoids and statins may potentiate the cancer-retardant efficacy of IGF-I down-regulation. Med Hypotheses. 2001;56(1):12–6.PubMedCrossRef
77.
go back to reference Atil B, Sieczkowsky E, Hohenegger M. Statins reduce endogenous dolichol levels in the neuroblastoma cell line SH-SY5Y. BMC Pharmacol Toxicol. 2012;13(Suppl 1):A51.PubMedCentralCrossRef Atil B, Sieczkowsky E, Hohenegger M. Statins reduce endogenous dolichol levels in the neuroblastoma cell line SH-SY5Y. BMC Pharmacol Toxicol. 2012;13(Suppl 1):A51.PubMedCentralCrossRef
78.
go back to reference Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57(1):62–6.PubMedCrossRef Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57(1):62–6.PubMedCrossRef
79.
go back to reference Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60–8.PubMedCrossRef Paiva H, Thelen KM, Van Coster R, Smet J, De Paepe B, Mattila KM, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005;78(1):60–8.PubMedCrossRef
80.
go back to reference Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7.PubMedCrossRef Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol. 2007;49(23):2231–7.PubMedCrossRef
81.
go back to reference Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003;18(1–4):113–24.PubMedCrossRef Passi S, Stancato A, Aleo E, Dmitrieva A, Littarru GP. Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA. Biofactors. 2003;18(1–4):113–24.PubMedCrossRef
82.
go back to reference Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol. 2004;194(1):10–23.PubMedCrossRef Schaefer WH, Lawrence JW, Loughlin AF, Stoffregen DA, Mixson LA, Dean DC, et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol. 2004;194(1):10–23.PubMedCrossRef
83.
go back to reference Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. Eur J Pharmacol. 2013;711(1–3):1–9.PubMedCrossRef Vaughan RA, Garcia-Smith R, Bisoffi M, Conn CA, Trujillo KA. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. Eur J Pharmacol. 2013;711(1–3):1–9.PubMedCrossRef
84.
go back to reference Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12.PubMedCrossRef Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99(10):1409–12.PubMedCrossRef
85.
go back to reference Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012;40(4):88–95.PubMedCrossRef Deichmann RE, Lavie CJ, Dornelles AC. Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins. Phys Sportsmed. 2012;40(4):88–95.PubMedCrossRef
86.
go back to reference Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 2002;37(2):185–92.PubMedCrossRef Ownby SE, Hohl RJ. Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells. Lipids. 2002;37(2):185–92.PubMedCrossRef
87.
go back to reference Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, et al. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223(1):39–45.PubMedCrossRef Nishimoto T, Ishikawa E, Anayama H, Hamajyo H, Nagai H, Hirakata M, et al. Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs. Toxicol Appl Pharmacol. 2007;223(1):39–45.PubMedCrossRef
88.
go back to reference Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol. 2004;200(3):237–50.PubMedCrossRef Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, et al. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol. 2004;200(3):237–50.PubMedCrossRef
89.
go back to reference Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, De Raynaud Mauverger E, Lacampagne A. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012;259(2):263–8.PubMedCrossRef Sirvent P, Fabre O, Bordenave S, Hillaire-Buys D, De Raynaud Mauverger E, Lacampagne A. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. Toxicol Appl Pharmacol. 2012;259(2):263–8.PubMedCrossRef
90.
go back to reference Hubal MJ, Reich KA, De Biase A, Bilbie C, Clarkson PM, Hoffman EP, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011;44(3):393–401.PubMed Hubal MJ, Reich KA, De Biase A, Bilbie C, Clarkson PM, Hoffman EP, et al. Transcriptional deficits in oxidative phosphorylation with statin myopathy. Muscle Nerve. 2011;44(3):393–401.PubMed
91.
go back to reference De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333–7.PubMedCrossRef De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, et al. Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol. 1996;42(3):333–7.PubMedCrossRef
92.
go back to reference Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004;177(1):183–8.PubMedCrossRef Phillips PS, Phillips CT, Sullivan MJ, Naviaux RK, Haas RH. Statin myotoxicity is associated with changes in the cardiopulmonary function. Atherosclerosis. 2004;177(1):183–8.PubMedCrossRef
93.
go back to reference Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81(5):650–3.PubMedCrossRef Schick BA, Laaksonen R, Frohlich JJ, Paiva H, Lehtimaki T, Humphries KH, et al. Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin. Clin Pharmacol Ther. 2007;81(5):650–3.PubMedCrossRef
94.
go back to reference Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci. 2013;325(1–2):142–7.PubMedCrossRef Stringer HA, Sohi GK, Maguire JA, Cote HC. Decreased skeletal muscle mitochondrial DNA in patients with statin-induced myopathy. J Neurol Sci. 2013;325(1–2):142–7.PubMedCrossRef
95.
go back to reference Bouitbir J, Daussin F, Charles AL, Rasseneur L, Dufour S, Richard R, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46(3):367–73.PubMedCrossRef Bouitbir J, Daussin F, Charles AL, Rasseneur L, Dufour S, Richard R, et al. Mitochondria of trained skeletal muscle are protected from deleterious effects of statins. Muscle Nerve. 2012;46(3):367–73.PubMedCrossRef
96.
go back to reference Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690–2.PubMedCrossRef Bell DS. Resolution of statin-induced myalgias by correcting vitamin D deficiency. South Med J. 2010;103(7):690–2.PubMedCrossRef
97.
go back to reference Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9.PubMedCrossRef Gupta A, Thompson PD. The relationship of vitamin D deficiency to statin myopathy. Atherosclerosis. 2011;215(1):23–9.PubMedCrossRef
98.
go back to reference Shewmon DA, Craig JM. Creatine supplementation prevents statin-induced muscle toxicity. Ann Intern Med. 2010;153(10):690–2.PubMedCrossRef Shewmon DA, Craig JM. Creatine supplementation prevents statin-induced muscle toxicity. Ann Intern Med. 2010;153(10):690–2.PubMedCrossRef
Metadata
Title
The Effects of Statin Medications on Aerobic Exercise Capacity and Training Adaptations
Authors
Zsolt Murlasits
Zsolt Radák
Publication date
01-11-2014
Publisher
Springer International Publishing
Published in
Sports Medicine / Issue 11/2014
Print ISSN: 0112-1642
Electronic ISSN: 1179-2035
DOI
https://doi.org/10.1007/s40279-014-0224-4

Other articles of this Issue 11/2014

Sports Medicine 11/2014 Go to the issue